US2011306630A1PendingUtilityA1

Pharmaceutical compositions comprising colloidal silicon dioxide

Assignee: HAEBERLIN BARBARAPriority: Sep 28, 2001Filed: Jun 13, 2011Published: Dec 15, 2011
Est. expirySep 28, 2021(expired)· nominal 20-yr term from priority
A61P 37/08A61P 7/06A61P 37/06A61P 9/08A61P 5/00A61P 37/02A61P 5/14A61P 27/14A61P 3/10A61P 35/00A61P 29/00A61P 31/10A61P 31/00A61P 25/28A61P 27/02A61P 25/00A61P 1/04A61P 17/02A61P 17/08A61P 19/02A61P 13/12A61P 1/16A61P 11/06A61P 11/00A61P 17/14A61P 17/06A61P 17/00A61P 17/04A61P 19/08A61P 21/04A61K 9/2009A61K 9/146A61K 31/435A61K 9/2027A61K 31/445A61K 9/145A61K 9/0056A61K 9/2077A61K 9/20
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight. 
     
     
         2 . A pharmaceutical composition according to  claim 1 , wherein 250 mg of the composition, when compressed using a force of 8 to 11 kN with a 9 mm die and standard flat punches, forms a tablet having a hardness of 35 to 80 N and a disintegration time of 3 minutes or less. 
     
     
         3 . A composition according to  claim 1 , wherein the composition is in the form of a dispersible tablet. 
     
     
         4 . A composition according to  claim 3 , wherein the tablet has a disintegration time of 90 seconds or less. 
     
     
         5 . A composition as claimed in  claim 1 , wherein the macrolide is rapamycin, ascomycin or a derivative thereof. 
     
     
         6 . A composition as claimed in  claim 1 , wherein the derivative of rapamycin is 40-o-(2-hydroxy)ethyl-rapamycin. 
     
     
         7 . (canceled) 
     
     
         8 . A method of administering a pharmaceutical composition of  claim 1  to a subject in need of such therapy which comprises (i) contacting the composition with an aqueous solution (ii) allowing the composition to disperse in the aqueous solution to form a dispersed mixture and (ii) ingesting the dispersed mixture. 
     
     
         9 . (canceled) 
     
     
         10 . A process for producing a macrolide-containing dispersible tablet, comprising preparing a macrolide solid dispersion, mixing the macrolide solid dispersion with a disintegrant and colloidal silicon dioxide to form a pharmaceutical composition and compressing the pharmaceutical composition to form the dispersible tablet.

Join the waitlist — get patent alerts

Track US2011306630A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.